Alterity Therapeutics, ATH434, Multiple System Atrophy, MSA, Parkinson’s Disease, Neurodegenerative Disease, Phase 2, Phase 3, UMSARS,

MELBOURNE, Australia and SAN FRANCISCO, USA — October 5, 2026 Alterity Therapeutics Limited announced new analyses from its randomized,...